CUTISS secures 25 million Swiss francs from investors

21 May 2024 09:27

Supporting partner

Schlieren - CUTISS has closed a first Series C financing round in the amount of 25 million Swiss francs. With this, the life sciences company with a focus on regenerative medicine can proceed to Phase 3 clinical trials for its personalized skin tissue therapy.

CUTISS has secured investment in the amount of 25 million Swiss francs in its first Series C financing round. This was led by the Ticino-based family office of Giammaria Giuliani, an Italian healthcare investor, and a North American family represented by Shiloh Advisors.

CUTISS, a life sciences company founded in 2016 and headquartered at the Bio-Technopark Schlieren-Zurich, writes in a press release that this first closing will allow the company to proceed to Phase 3 clinical trials for its personalized skin tissue therapy called denovoSkin. It was only in April 2024 that the company, which is a spin-off from the University of Zurich and Children's Hospital Zurich, announced the positive results of its Phase 2 clinical trial in people with severe skin injuries that cover large areas of the body. Furthermore, according to the press release, the investment will be put towards advancing the commercialization and clinical viability of the machine developed by CUTISS for bioengineering its personalized human skin tissue therapy.

“This funding will enable us to continue working at speed to reach our critical development milestones”, comments Dr. Daniela Marino, CEO and co-founder of CUTISS. “The recent positive Phase 2 clinical trial results for denovoSkin have fueled our determination to innovate further in regenerative medicine”, she adds. However, the Series C financing round is still ongoing, with the company continuing to “invite additional investors to support our mission”. ce/mm

Supporting partner

Swiss Pavilion Digital